Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Rhea-AI Summary
Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) announced that CEO David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026, to be held 28-29 July 2026, hosting 1-on-1 meetings with U.S. investors.
Alterity is a clinical-stage company focused on Multiple System Atrophy (MSA) and related Parkinsonian disorders. The company is preparing a Phase 3 pivotal trial of lead asset ATH434, which has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 MSA study and positive data in an open-label Phase 2 trial in advanced MSA.
Positive
- None.
Negative
- None.
News Market Reaction – ATHE
In the Jul 21 session, ATHE gained 5.06%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | FDA pathway update | Positive | -6.8% | FDA minutes confirmed a single pivotal Phase 3 trial plus confirmatory evidence could support an NDA. |
| Jun 09 | FDA trial alignment | Positive | +21.9% | FDA aligned with the pivotal Phase 3 design after positive Phase 2 efficacy findings. |
| May 19 | Phase 2 data update | Positive | -1.5% | New Phase 2 analyses supported advancement of ATH434 into a Phase 3 program. |
| May 11 | MRI biomarker publication | Positive | +3.0% | Peer-reviewed publication reported QSM MRI utility in detecting disease-specific brain iron accumulation. |
| May 07 | Conference presentations | Neutral | +3.3% | Company announced May medical conference presentations covering its MSA development program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and regulatory announcements produced mixed reactions, with three declines and two gains across the selected historical events.
Key Terms
double-blind medical
placebo-controlled medical
open label medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in the BTIG Biotechnology Conference 2026 taking place virtually 28-29 July 2026.
At the conference, Dr. Stamler will host 1-on-1 meetings with investors in the United States.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
